Who founded Pionyr Immunotherapeutics?

Pionyr Immunotherapeutics was founded by Matthew F. Krummel, Ph.D. in 2015.

Who are Pionyr Immunotherapeutics's investors?

Pionyr Immunotherapeutics's investors include Mission Bay Capital, Mission Biocapital, New Enterprise Associates (NEA), OUP (Osage University Partners), Sofinnova Ventures, Sofinnova Venture Partners.

How much funding has Pionyr Immunotherapeutics raised?

Pionyr Immunotherapeutics has disclosed $45M raised across 2 rounds.

Where is Pionyr Immunotherapeutics headquartered?

Pionyr Immunotherapeutics is headquartered in San Francisco, US.

Pionyr Immunotherapeutics

San Francisco, US · Founded 2015 · Delaware corporation · 53 employees on LinkedIn · 6 known investors

Healthtech

Founders & leadership

Pionyr Immunotherapeutics was founded in 2015 by Matthew F. Krummel, Ph.D..

Matthew F. Krummel, Ph.D.Founder

Steven P. JamesExecutive

Leon Chen, Ph.D.Named on SEC filing

Carol GallagherNamed on SEC filing

Joshua Resnick, M.D.Named on SEC filing

Board

Michael PowellBoard director

Investors · 6

Mission Bay CapitalSan Francisco

Mission BiocapitalSan Francisco · $500K

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

Sofinnova VenturesMenlo Park · $100K – $15M

Sofinnova Venture PartnersreportedMenlo Park

Reported raises · per SEC filings

Form D private placements

$45M disclosed across 2 rounds · 2017–2018

▶$7MraisedApr 2018 · 2 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Carol GallagherDirector
Joshua Resnick, M.D.Director
Matthew F. Krummel, Ph.D.Director
Leon Chen, Ph.D.Director
Steven P. JamesExecutive Officer, Director, Promoter
Michael PowellDirector

Offering amount: $7M
Amount sold: $7M
First sale: Mar 2018
Incorporated: Corporation, Delaware, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$38MraisedDec 2017 · 16 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Leon Chen, Ph.D.Director
Matthew F. Krummel, Ph.D.Director
Michael PowellDirector
Carol GallagherDirector
Joshua Resnick, M.D.Director
Steven P. JamesExecutive Officer, Director, Promoter

Offering amount: $62M
Amount sold: $38M
First sale: Dec 2017
Incorporated: Corporation, Delaware, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline - BioSpacebiospace.com · Jan 2026

Pionyr Immunotherapeutics gains meaty $62M series B | Fierce Biotechfiercebiotech.com · Dec 2017

Pionyr Immunotherapeutics Completes $62M in Series B Financing - FinSMEsfinsmes.com · Dec 2017

Frequently asked questions

Who founded Pionyr Immunotherapeutics?: Pionyr Immunotherapeutics was founded by Matthew F. Krummel, Ph.D. in 2015.
Who are Pionyr Immunotherapeutics's investors?: Pionyr Immunotherapeutics's investors include Mission Bay Capital, Mission Biocapital, New Enterprise Associates (NEA), OUP (Osage University Partners), Sofinnova Ventures, Sofinnova Venture Partners.
How much funding has Pionyr Immunotherapeutics raised?: Pionyr Immunotherapeutics has disclosed $45M raised across 2 rounds.
Where is Pionyr Immunotherapeutics headquartered?: Pionyr Immunotherapeutics is headquartered in San Francisco, US.